The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.

Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

People with intermediate-risk scores on coronary artery calcium testing who received statins and intensive health coaching ...

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...

INGELHEIM, Germany and PLEASANTON, Calif., March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...